MYLAN-ALMOTRIPTAN 12.5 MG — DIN 02398443
ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 12.5 MG · MYLAN PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is MYLAN-ALMOTRIPTAN?
MYLAN-ALMOTRIPTAN 12.5 MG contains ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 12.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02398443, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Jul-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYLAN-ALMOTRIPTAN used for?
Acute treatment of migraine attacks with or without aura in adults and adolescents (12-17 years of age). Not for prophylactic therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Almotriptan cost around the world?
Almotriptan is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A); Luxembourg publishes a reimbursement. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Spain | PVP con IVA (public price) | 27 | 30 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 5 | 13 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 5 | SEK███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
51 pack listings across 37 brand entries and 5 price bases, refreshed 05 Sep 2026. Ranges span every Almotriptan pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Almotriptan in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Almotriptan, across 13 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MYLAN PHARMACEUTICALS ULC | 2 | 2 | MYLAN-ALMOTRIPTAN | Sourceable in Canada |
| PRO DOC LIMITEE | 1 | 1 | ALMOTRIPTAN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | SANDOZ ALMOTRIPTAN | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | ALMOTRIPTAN | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-ALMOTRIPTAN | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-ALMOTRIPTAN | No marketed DIN |
| JAMP PHARMA CORPORATION | 2 | 0 | JAMP ALMOTRIPTAN | No marketed DIN |
| MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | 2 | 0 | AXERT 12.5MG, AXERT 6.25MG | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-ALMOTRIPTAN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 12.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 6.25 mg and 12.5 mg strengths). |
| Storage | Not explicitly detailed in provided text (Table of Contents refers to page 29, but text ends earlier). Typically 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Almotriptan |
|---|---|
| ATC code | N02CC05 |
| AHFS class | 28:32.28 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02398443 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2398443 |
| Brand name | MYLAN-ALMOTRIPTAN |
| Generic / active ingredient | ALMOTRIPTAN (ALMOTRIPTAN MALATE) : 12.5 MG |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | N02CC05 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02CC |
| Current status | MARKETED |
| Status date | 22-Jul-2013 |
| Original market date | 2013-07-22 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Oral. Starting dose 6.25-12.5 mg. Max 25 mg/24 hours. If renal/hepatic impairment, max 12.5 mg/24 hours. If headache returns, a second dose may be taken after 2 hours.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; ischemic cardiac, cerebrovascular, or peripheral vascular syndromes; uncontrolled hypertension; use within 24 hours of other 5-HT1 agonists or ergot-type meds; severe hepatic impairment.
Warnings and precautions
Use only where migraine diagnosis is clear. Risk of myocardial ischemia/infarction. Monitor patients with cardiovascular risk factors. Risk of Medication Overuse Headache.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALMOTRIPTAN | 12.5 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02424029 |
| ALMOTRIPTAN | 12.5 MG | TABLET | SANIS HEALTH INC | MARKETED | 02466821 |
| MYLAN-ALMOTRIPTAN | 6.25 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | 02398435 |
| SANDOZ ALMOTRIPTAN | 12.5 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02405334 |
| TEVA-ALMOTRIPTAN | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02434849 |
| APO-ALMOTRIPTAN | 12.5 MG | TABLET | APOTEX INC | DORMANT | 02405806 |
| APO-ALMOTRIPTAN | 6.25 MG | TABLET | APOTEX INC | DORMANT | 02405792 |
| AXERT 12.5MG | 12.5 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | 02248129 |
| AXERT 6.25MG | 6.25 MG | TABLET | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | CANCELLED POST MARKET | 02248128 |
| JAMP ALMOTRIPTAN | 6.25 MG | TABLET | JAMP PHARMA CORPORATION | APPROVED | 02556022 |
2 · Same class — other molecules in ATC N02CC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Rizatriptan | ACCEL-RIZATRIPTAN ODT · ACT RIZATRIPTAN · ACT RIZATRIPTAN ODT · AG-RIZATRIPTAN ODT · +36 more | 85 | 34 | Yes |
| Sumatriptan | ACT SUMATRIPTAN · AG-SUMATRIPTAN · APO-SUMATRIPTAN · AVA-SUMATRIPTAN · +27 more | 80 | 32 | Yes |
| Eletriptan | APO-ELETRIPTAN · APO-ELETRIPTAN TABLETS · AURO-ELETRIPTAN · ELETRIPTAN · +6 more | 20 | 16 | Yes |
| Zolmitriptan | AG-ZOLMITRIPTAN ODT · APO-ZOLMITRIPTAN · APO-ZOLMITRIPTAN RAPID · AURO-ZOLMITRIPTAN · +33 more | 45 | 15 | Yes |
| Almotriptan | ALMOTRIPTAN · APO-ALMOTRIPTAN · AXERT 12.5MG · AXERT 6.25MG · +5 more | 13 | 6 | Yes |
| Frovatriptan | APO-FROVATRIPTAN · FROVA · FROVATRIPTAN · JAMP FROVATRIPTAN · +2 more | 6 | 5 | Yes |
| Naratriptan | AMERGE · APO-NARATRIPTAN · SANDOZ NARATRIPTAN · TEVA-NARATRIPTAN | 7 | 3 | Yes |
| Sumatriptan And Naproxen | SUVEXX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02CD | Atogepant · Eptinezumab · Erenumab · Fremanezumab · Galcanezumab · +2 more | 17 | 15 |
| N02CA | Dihydroergotamine · Ergotamine · Ergotamine, Combinations Excl. Psycholeptics · Ergotamine, Combinations With Psycholeptics · Methysergide | 15 | 2 |
| N02CX | Clonidine · Pizotifen | 3 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MYLAN-ALMOTRIPTAN called?
The same molecule, Almotriptan, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Almogran | Latin | Sweden |
| Almotriptan Orifarm | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.